Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893307 | PMC |
| http://dx.doi.org/10.1016/j.lansea.2025.100549 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association.
Europace
March 2025
Clinical Cardiac Academic Group, Genetic and Cardiovascular Sciences Institute, City-St George's University of London, London, UK.
Atrial fibrillation (AF) is one of the most common cardiac diseases and a complicating comorbidity for multiple associated diseases. Many clinical decisions regarding AF are currently based on the binary recognition of AF being present or absent with the categorical appraisal of AF as continued or intermittent. Assessment of AF in clinical trials is largely limited to the time to (first) detection of an AF episode.
View Article and Find Full Text PDFSuccessful Percutaneous Extraction of a WATCHMAN FLX Device From the Left Ventricular Outflow Tract.
JACC Case Rep
January 2025
Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Although rare, embolization of left atrial appendage occlusion (LAAO) devices carries a significant morbidity and mortality burden.
Case Summary: An asymptomatic 77-year-old woman with inability to tolerate anticoagulation due to gastrointestinal bleeding presented for 45-day transesophageal echocardiography following LAAO with a Watchman device, which demonstrated incidental device migration to the left ventricular outflow tract (LVOT). Percutaneous extraction was performed using a novel technique with rat tooth/alligator forceps to successfully retrieve the Watchman from the LVOT using a transaortic approach.
CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy.
Eur J Haematol
March 2025
Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Background: One of the limiting toxicities of BTKi is the development of atrial fibrillation (AF), with an incidence of 3%-16%.
Aim: This study aimed to identify patients with chronic lymphocytic leukemia (CLL) starting both first- and second-generation BTKis who are at high risk of developing AF using a machine learning approach.
Methods: The CLL cohort is based on data obtained from electronic medical records from Maccabi, the second-largest healthcare organization in Israel.
The burden of atrial fibrillation and unmet needs of its management in Southeast Asia and South Asia.
Lancet Reg Health Southeast Asia
March 2025
Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Urban-Rural Differences in the Outcomes of Patients Hospitalized for Cardiac Implantable Electronic Devices Infection in the United States.
J Cardiovasc Electrophysiol
March 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Background: Cardiac implantable electronic device (CIED) infections are a serious complication associated with significant morbidity, mortality, and healthcare costs. Despite guideline recommendations for complete device removal, disparities in healthcare access and resource availability between urban and rural settings may influence patient outcomes. This study aims to evaluate rural-urban disparities in the management and outcomes of patients hospitalized with CIED infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!